Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, ifosfamide, and cisplatin in treating patients who have metastatic testicular cancer that has recurred following treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical Research Council
• Treatments: Albumin-Bound Paclitaxel; Cisplatin; Ifosfamide; Isophosphamide mustard; Paclitaxel

Criteria

DISEASE CHARACTERISTICS:

• Metastatic nonseminomatous germ cell tumor of the testis

• In first relapse following first line treatment with bleomycin, etoposide, and cisplatin

• Biopsy proven germ cell tumor OR

• Rising tumor markers (alpha fetoprotein and/or human chorionic gonadotropin)

• No brain metastases

PATIENT CHARACTERISTICS:

Age:

• 16 to 64

Performance status:

• 0-2

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Glomerular filtration rate greater than 50 mL/min

Other:

• No other prior malignancy except curatively treated nonmelanomatous skin cancer or superficial bladder cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• See Disease Characteristics

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified

Other:

• No prior experimental drugs